[HTML][HTML] Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia

T Niihori, Y Aoki, H Ohashi, K Kurosawa… - Journal of human …, 2005 - nature.com
T Niihori, Y Aoki, H Ohashi, K Kurosawa, T Kondoh, S Ishikiriyama, H Kawame, H Kamasaki…
Journal of human genetics, 2005nature.com
Noonan syndrome (NS) is characterized by short stature, characteristic facial features, and
heart defects. Recently, missense mutations of PTPN11, the gene encoding protein tyrosine
phosphatase (PTP) SHP-2, were identified in patients with NS. Further, somatic mutations in
PTPN11 were detected in childhood leukemia. Recent studies showed that the phosphatase
activities of five mutations identified in NS and juvenile myelomonocytic leukemia (JMML)
were increased. However, the functional properties of the other mutations remain …
Abstract
Noonan syndrome (NS) is characterized by short stature, characteristic facial features, and heart defects. Recently, missense mutations of PTPN11, the gene encoding protein tyrosine phosphatase (PTP) SHP-2, were identified in patients with NS. Further, somatic mutations in PTPN11 were detected in childhood leukemia. Recent studies showed that the phosphatase activities of five mutations identified in NS and juvenile myelomonocytic leukemia (JMML) were increased. However, the functional properties of the other mutations remain unidentified. In this study, in order to clarify the differences between the mutations identified in NS and leukemia, we examined the phosphatase activity of 14 mutants of SHP-2. We identified nine mutations, including a novel F71I mutation, in 16 of 41 NS patients and two mutations, including a novel G503V mutation, in three of 29 patients with leukemia. Immune complex phosphatase assays of individual mutants transfected in COS7 cells showed that ten mutants identified in NS and four mutants in leukemia showed 1.4-fold to 12.7-fold increased activation compared with wild-type SHP-2. These results suggest that the pathogenesis of NS and leukemia is associated with enhanced phosphatase activity of mutant SHP-2. A comparison of the phosphatase activity in each mutant and a review of previously reported cases showed that high phosphatase activity observed in mutations at codons 61, 71, 72, and 76 was significantly associated with leukemogenesis.
nature.com